Table 4.

Effects of the different variants on therapeutics and vaccines

Vaccines	B.1.1.7	B1.351	P.1	Other VOC/Is
mRNA Vaccine Pfizer/BioNTech BNT162b2	90–95% efficacy in a setting of 81.5% B.1.1.7 prevalence, estimated by SGTF [66]	100% effective (53–100% CI), based on six cases in placebo group versus none in vaccine group [42]	No published data	No published data
Protein subunit vaccine Novavax NVX-CoV2373	85.6% efficacy against B.1.1.7 95.6% efficacy against non-B.1.1.7 Only one severe case [67]	60% efficacy in HIV(–) subjects in South Africa (92.7% of sequences were B.1.351), 51% against B.1.351 specifically No severe cases, too few events to conclude [67]	No published data	No published data
Adenovirus vaccine Janssen (J&J) Ad26.COV2.S	No published data	52% efficacy against moderate disease and 72% against severe/critical disease in South Africa (>95% of sequences were B.1.351), versus 72% efficacy in USA 100% protection against death [68]	No published data	Insufficient data for P.2, No data for others
Adenovirus vaccine AstraZeneca AZD1222	70% efficacy versus B.1.1.7 versus 81% against non-B.1.1.7 [69]	10% efficacy against mild and moderate disease in young people, no data against severe disease [45]	No published data	No published data
mAb therapies:
LY-CoV555 (Bamlanivimab)	Susceptible	Resistant [22,55]	Resistant [22,55]	B.1.429: Resistant [64]
Etesevimab	Resistant [33]	Resistant [33]	Resistant [33]	No data
REGN10933 and REGN10987 (Casirivimab + Imdevimab)	Susceptible	Partially resistant to Casirimivab, but Imdevimab is effective [33,55]	Partially resistant to Casirivimab but Imdevimab is effective [33,55]	B.1.526 with E484k is resists Casirivimab [70]

Vaccine efficacy is given as efficacy against symptomatic infection unless otherwise specified).

SGTF, S-gene target failure.